Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$5MCash on Hand
2.6mo Cash Runway
Follow QUCY by emailGet an email when QUCY reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about QUCY, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Earnings Quantum Cyber reported first revenue of $966,833 for the quarter ended September 30, 2026, from its Bridgeport metal stamping business. It also disclosed an $8.0 million funding commitment from CEO David Lazar and a $250,000 Boustead settlement. Form 8-K · SEC filing · Press release
Nov 12, 2026 ·
Deal Quantum Drones, a subsidiary, amended its IP license with Project LightShift on Nov 6, 2026. The amendment expands the field to maritime and government security uses, allows sublicensing without consent, and makes the license royalty-bearing after four times Development Costs are recovered. Form 8-K · SEC filing
Nov 12, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 9, 2026 ·
Financing Quantum Cyber N.V. filed a prospectus supplement for an at-the-market offering of up to $100,000,000 of ordinary shares through Titan Partners Securities LLC, with a 3% commission. The stock last traded at $1.39 on October 8, 2026. Form 424B5 · SEC filing
Oct 9, 2026 ·
Financing Quantum Cyber N.V. entered a sales agreement with Titan Partners Securities LLC for an at-the-market offering of up to $100,000,000 of ordinary shares, with a 3.0% commission to the agent. Proceeds are intended for capital expenditures, software development, production expansion, acquisitions, and working capital. Form 8-K · SEC filing
Sep 25, 2026 ·
Quantum Cyber narrowed its strategy to three pillars: one-way attack and interceptor drones, the quantum antenna licensed from Project LightShift, and the MAHCA operating system, with maritime programs de-emphasized. Form 8-K · SEC filing · Press release
Sep 25, 2026 ·
Filed audited combined financial statements for Arcade Technology LLC and Arcade Realty LLC for 2025 and 2024, showing 2025 revenue of $4,339,242 and a net loss of $(118,846), and pro forma combined financial information for Quantum Cyber N.V. Pro forma figures are illustrative only. Form 8-K/A · SEC filing · Press release
Aug 14, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Apr 2026 · N/A · Results Expected · Evaluation of the Efficacy and Safety of Dallixa® Eyebrow Serum (Produced by Quantum Aesthetics Cosmetics, Turkey) in Subjects With Eyebrow Hypotrichosis Registry primary completion date, not a results date
Feb 2026 · Phase 4 · Results Expected · Efficacy and Safety of Dallixa® Eyelash Serum in Idiopathic Eyelash Hypotrichosis Registry primary completion date, not a results date
Jul 2025 · N/A · Results Expected · Open, Non-comparative Study to Evaluate the Effectiveness and Safety of the Medical Device KOS® XL for the Restoration and/or Augmentation of Facial Volume Registry primary completion date, not a results date
Jul 2025 · N/A · Results Expected · Open, Non-comparative Study to Evaluate the Effectiveness and Safety of the Medical Device KOS® L in Correcting Moderate or Severe Nasolabial Folds Registry primary completion date, not a results date
Jul 2025 · N/A · Results Expected · Open, Non-comparative Study to Evaluate the Effectiveness and Safety of the Medical Device KOS® M in Lip Augmentation Registry primary completion date, not a results date
Jul 2025 · N/A · Results Expected · Open, Non-comparative Study to Evaluate the Effectiveness and Safety of the Medical Device KOS® S in the Correction of Moderate or Severe Infraorbital Hollowing Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not QUCY's own candidates): Ramipril.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
QUCY holds $5M in cash and short-term investments (as of Sep 30, 2026) and burns about $5.7M/quarter from operations,
an estimated runway of 2.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:80 · High
Cash runway 3 months +40
ATM program on file since Oct 2026 +15
Shelf registration (S-3, Jun 2026) +10
Going-concern doubt in the latest 10-Q +15These conditions raised substantial doubt about the Company’s ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued.10-Q, Nov 2026
Share count 87,241,735 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full QUCY picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for QUCY and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.